Noile-Immune Biotech (4893), Earnings Report: Operating Loss of 419 Million Yen

Noile-Immune Biotech (4893) has released its financial results, reporting an operating loss of 419 million yen, an ordinary loss of 370 million yen, and a net loss of 372 million yen, with a net loss per share of 8.59 yen. The results reflect the ongoing upfront investments in research and development typical for a clinical-stage biotechnology company.

Despite the recurring operational losses and a retained earnings balance of approximately -4.519 billion yen as of June 30, 2026—reflecting past R&D investments—the company maintains an exceptionally robust financial foundation. The equity ratio stands at a high 97.3%, with zero interest-bearing debt, and cash and cash equivalents of 3.54 billion yen. The company's solid capital structure provides a strong cushion while advancing its pipeline toward future commercialization.

---

Correction (September 19, 2026)：The affected figures and reporting-period labels were corrected after checking the source disclosure. Source disclosure